- Open Access
Systemic inhibition of myeloid dendritic cells by circulating HLA class I molecules in HIV-1 infection
- Jinghe Huang†1,
- Maha Al-Mozaini†1, 2, 3,
- Jerome Rogich1,
- Mary F Carrington1,
- Katherine Seiss1,
- Florencia Pereyra1,
- Mathias Lichterfeld2 and
- Xu G Yu1Email author
© Huang et al; licensee BioMed Central Ltd. 2012
- Received: 14 October 2011
- Accepted: 30 January 2012
- Published: 30 January 2012
HIV-1 infection is associated with profound dysfunction of myeloid dendritic cells, for reasons that remain ill-defined. Soluble HLA class I molecules can have important inhibitory effects on T cells and NK cells, but may also contribute to reduced functional properties of professional antigen-presenting cells. Here, we investigated the expression of soluble HLA class I isoforms during HIV-1 infection and assessed their functional impact on antigen-presenting characteristics of dendritic cells.
Soluble HLA class I molecules were highly upregulated in progressive HIV-1 infection as determined by quantitative Western blots. This was associated with strong increases of intracellular expression of HLA class I isoforms in dendritic cells and monocytes. Using mixed lymphocyte reactions, we found that soluble HLA class I molecules effectively inhibited the antigen-presenting properties of dendritic cells, however, there was no significant influence of HLA class I molecules on the cytokine-secretion properties of these cells. The immunomodulatory effects of soluble HLA class I molecules were mediated by interactions with inhibitory myelomonocytic MHC class I receptors from the Leukocyte Immunoglobulin Like Receptor (LILR) family.
During progressive HIV-1 infection, soluble HLA class I molecules can contribute to systemic immune dysfunction by inhibiting the antigen-presenting properties of myeloid dendritic cells through interactions with inhibitory myelomonocytic HLA class I receptors.
- dendritic cells
- Leukocyte Immunoglobulin Like Receptor (LILR)
HIV-1 infection leads to massive immune activation that results from direct stimulation of immune cells by HIV-1 antigens, the release of large amounts of pro-inflammatory cytokines, and the systemic circulation of bacterial polysaccharide antigens after translocation from intestinal mucosal tissues . This immune activation can cause counter-regulatory activities of inhibitory components of the immune system, such as increased recruitment of regulatory T cells , upregulation of inhibitory receptors on antigen-specific T cells [3, 4], and enhanced expression of immunoregulatory receptors on dendritic cells [5, 6]. These mechanisms may in part protect the host against immune pathology by limiting over activation of the immune system, but might also contribute to viral persistence by propagating immune dysfunction. Identifying immunomodulatory mechanisms that contribute to this functional disarray between stimulatory and inhibitory immunological pathways is an important step in understanding the pathogenesis of HIV-1 infection.
HLA class I isoforms are heterodimeric molecules that consist of a 44-kDa polymorphic glycoprotein (α chain) that is noncovalently associated with the 12-kDa non-polymorphic β2-microglobulin. These molecules are expressed on the surface of all human cells and have important functions for presenting antigenic peptides, and for priming and maintaining T cell immune responses. In addition, HLA class I molecules can also occur as soluble agents in the serum or plasma [7, 8]. These soluble HLA class I molecules can either occur as intact, 44-kDa HLA class I heavy chains, or as 39-kDa variants that do not contain a transmembrane domain and result from alternative splicing . 35-kDa species of soluble HLA class I isoforms have also been described and most likely represent proteolytic breakdown products of intact HLA class I heavy chains . These soluble HLA molecules can have important systemic immunoregulatory effects by influencing survival and apoptosis of antigen-specific T cells and NK cells through interactions with receptors from the KIR or the C-type lectin family [11–13]. Leukocyte Immunoglobulin Like Receptors (LILR) represent an alternative group of HLA class I receptors that are predominantly expressed on dendritic cells and monocytes, which, as professional antigen-presenting cells, have central roles for generating adaptive immune responses and regulating immune activation through cytokine secretion . Upon triggering by HLA molecules, these receptors can influence functional properties of professional antigen-presenting cells in an inhibitory or stimulatory fashion, and in this way importantly influence pathogen-specific immune defense mechanisms. During HIV-1 infection, the quantity of soluble HLA class I isoforms is increased in the plasma , but how these molecules can specifically affect the functional characteristics of circulating dendritic cells during HIV-1 infection is unclear at present. In this study, we show that soluble HLA class I isoforms can importantly alter the antigen-presenting properties of dendritic cells through interactions with the inhibitory myelomonocytic MHC class I receptors. These data indicate a previously unrecognized immunoregulatory pathway that contributes to immune dysfunction of dendritic cells in HIV-1 infection.
To investigate immunoregulatory effects of soluble HLA class I isoforms in HIV-1 infection, we initially focused on quantifying the expression of HLA class I molecules in plasma and PBMC. For this purpose, a group of patients with chronic progressive HIV-1 infection (n = 14, mean viral load of 28,484 (8,104-449,000) copies/ml, mean CD4 cell counts of 412.5 (195-1000) cells/ul), a cohort of HIV-1 elite controllers (n = 14, viral load < 75 copies/ml, mean CD4 cell counts of 630 (188-1134) cells/μl) and a background population of HIV-1 negative persons (n = 16), were recruited.
Since increased levels of soluble HLA class I molecules in progressors may result from secretion by peripheral blood leukcoytes, we assessed intracellular expression of HLA class I molecules in different subsets of PBMC from our study cohorts. We observed a significant upregulation of intracellular HLA class I molecules in monocytes and dendritic cells from progressors (Figure 1C). Surface expression of HLA class I molecules on dendritic cells and monocytes was also higher in progressors than in the reference cohorts, but these differences were less pronounced than intracellular HLA class I expression (Figure 1D). Despite the fact that HIV-1 is known to downregulate HLA class I expression , we did not observe differences between the surface or intracellular expression of HLA class I molecules on T cells from the different study cohorts (data not shown), likely because the proportion of HIV-1 infected cells among all T lymphocytes in vivo is very low. Overall, these data suggest that secretion of soluble HLA class I molecules from dendritic cells and monocytes contributes to higher levels of soluble plasma HLA class I isoforms during progressive HIV-1 infection.
To investigate functional effects of soluble MHC class I isoforms, we focused on how these molecules can affect the stimulatory characteristics of myeloid dendritic cells which have key roles for the generation of adaptive immune responses. For this purpose, we tested the antigen-presenting properties of monocyte-derived dendritic cells (MDDC) in the presence of plasma from three study cohorts, using mixed lymphocyte reactions. Briefly, MDDC derived from identical donors were incubated for 30 minutes with respective plasma samples, washed aggressively, and co-cultured with CFSE-labeled allogeneic T cells from an HIV-1 negative study subject. Using flow cytometry assays, > 99% of the MDDC expressed the dendritic cell surface markers HLA-DR and CD11c, and HLA class I expression was detectable on > 98% of these cells (Additional File 2). In comparison to MDDC treated with plasma from HIV-1 negative persons or elite controllers, MDDC exposed to plasma from HIV-1 progressors had significantly reduced abilities to expand allogeneic T cells; this was true both for allogeneic CD4 and CD8 T cell responses.
As the most effective professional antigen-presenting cells, dendritic cells play critical roles for generating, maintaining and fine-tuning T-, B- and NK-cell mediated immune responses against HIV-1. In persons with natural control of HIV-1 infection, myeloid dendritic cells have superior antigen-presenting properties , while severe dysfunction of these cells has been reported in advanced stages of HIV-1 infection [17, 19]. This suggests that dendritic cell function can importantly influence clinical HIV-1 disease outcomes, but mechanistic pathways regulating the functional activity of these cells in HIV-1 infection remain poorly defined. In the present study, we demonstrate that soluble HLA class I molecules serve as systemic inhibitors of the functional properties of dendritic cells by interacting with inhibitory myelomonocytic MHC class I molecules from the LILR family. This indicates that in addition to their well-documented role for inhibiting various effector cell populations of the immune system [11–13], soluble HLA class I isoforms can contribute to progressive immune dysfunction in advanced HIV-1 infection by inhibiting professional antigen-presenting cells.
Multiple soluble factors have been identified that lead to systemic perturbations of immune system during HIV-1 infection. Most dominantly, such soluble factors include pro-inflammatory cytokines which are secreted in larger amounts by dendritic cells, monocytes, T cells and B cells during progressive HIV-1 infection [20, 21]. The source of the elevated levels of soluble HLA class I isoforms in the plasma of persons with progressive HIV-1 infection remains to be determined in detail, but increased intracellular accumulation of HLA class I isoforms in monocytes and dendritic cells suggests an autocrine effect by which release of these molecules from professional antigen-presenting cells autoregulates the functional properties of the secreting cells. Obviously, such a view does not exclude paracrine effects of soluble HLA class I molecules on other cell types localized in the surrounding microenvironment. Moreover, it is likely that soluble HLA class I molecules represent only one of multiple additional plasma components that regulate functional characteristics of dendritic cells; other intact or proteolytic fragments of plasma proteins may also have an important influence on dendritic cell functions, and remained to be investigated in future studies.
In this study, we found that soluble HLA class I molecules inhibit allostimulatory functions of DC through interactions with LILRB2, although cytokine secretion of dendritic cells remained unaffected by interactions between LILRB2 and soluble HLA class I molecules. This contrasts to the effects of soluble HLA-G molecules, which can alter both antigen-presenting properties and secretion of pro-inflammatory cytokines in dendritic cells . Together, these results suggest that individual functional properties of dendritic cells are differentially affected by triggering of LILRB2 through either classical or non-classical soluble HLA class I molecules. Generally, LILRB2 is highly upregulated on DC during chronic progressive HIV-1 infection  and seems to play an important role for inducing a tolerogenic profile of dendritic cells in the setting of immune tolerance after solid organ transplantation  and during pregnancy . In previous studies, tolerogenic effects of LILRB2 were attributed to interactions with membrane-bound HLA class I molecules; however, the results presented here suggest that binding of soluble HLA class I isotypes can similarly trigger LILRB2-mediated tolerogenic effects in DC. This is well in line with the recent description of strong interactions between LILRB2 and soluble HLA class I heavy chains .
Specific HLA class I alleles are among the best predictors of spontaneous HIV-1 disease progression [25, 26], and it will be important to determine whether associations between specific HLA class I isoforms and HIV-1 disease outcomes may be at least in part attributable to immunoregulatory effects of soluble HLA class I molecules on dendritic cells. Previous work has indeed shown that dendritic cell dysfunction resulting from interactions between specific membrane-bound HLA class I molecules and MHC class I receptors from the LILR family can critically determine HIV-1 disease progression [18, 27]. Moreover, HLA allele-specific interactions between soluble HLA class I heavy chains and immunoregulatory receptors from the LILR family have recently been demonstrated using a bead-based assay in a cell-free system . Future investigations will be necessary to compare functional immunoregulatory effects of individual soluble HLA class I isoforms associated with distinct HIV-1 disease outcomes.
Our data suggest that high levels of circulating soluble HLA class I molecules during progressive HIV-1 infection contribute to HIV-1-associated immune dysfunction by reducing stimulatory properties of myeloid dendritic cells. In this way, soluble HLA class I molecules may exert important immunoregulatory effects that propagate immune deficiency and viral persistence during HIV-1 infection.
Study participants were recruited at the Massachusetts General Hospital after giving written consent according to protocols approved by the local Institutional Review Board. HIV-1 patients were not taking antiretroviral therapy at the time of study participation.
Equal amounts of plasma were subjected to SDS-PAGE (Tris-Glycine 4-20% gels, Invitrogen), electroblotted and incubated with antibodies specific for HLA class I (clone T25.99 recognizing the HLA class I alpha3 domain , kindly provided by Dr. Soldano Ferrone, University of Pittsburg), β2-microglobulin (clone BBM.1, Santa Cruz Biotechnology) or β-actin (Abcam), followed by visualization with HRP-labeled secondary antibodies and ECL detection reactions (Amersham Biosciences).
Flow cytometric analysis of HLA-ABC expression
PBMCs were incubated with monoclonal antibodies against HLA-A, -B -C isoforms (clone W6/32, specific for HLA class I/β2-microglobulin complexes), CD14, HLA-DR, CD11c and a cocktail of lineage antibodies (CD3, CD14, CD16, CD19, CD56) for 20 min at room temperature. For intracellular detection of HLA-class I isoforms, cells were stained with surface antibodies, fixed and permeabilized using a commercial kit (Caltag), followed by intracellular staining with biotinylated HLA class I-specific antibodies (clone W6/32) and streptavidin-PE. Cells were analyzed on an LSRII (BD Biosciences) instrument.
Depletion of soluble HLA-ABC
Plasma samples were incubated with biotinylated HLA class I antibody (clone W6/32) for 1 h at room temperature, followed by immunomagnetic depletion of HLA class I molecules using anti-biotin magnetic beads (Invitrogen).
Preparation of Monocyte-derived dendritic cells (MDDC)
Freshly isolated PBMC were incubated for 60 min at 37°C to adhere monocytes. Adherent monocytes were propagated for 5d in the presence of 50 ng/ml GM-CSF (CellGenix). Immature myelomonocytic cells were then incubated with either full plasma or HLA-class I-depleted plasma at 37°C for 30 min, followed by aggressive washes. In some experiments, recombinant LILRB2 protein (R&D Systems) was added to full plasma for 1 h before adding to the MDDC. When indicated, MDDC were electroporated with LILRB2-specific siRNA as described before . MDDC were matured for 16 h using a previously described cytokine cocktail containing IL-1β, TNF-α, PGE-2, and IL-6 .
Dendritic cell functional assays
Matured MDDC were mixed with CFSE-labeled allogeneic T cells from identical, HIV-1 negative donors. After 6 consecutive days of culture, cells were stained with monoclonal CD4+ and CD8+ antibodies and analyzed by flow cytometry. For the detection of cytokine secretion in MDDC, immatured cells were stimulated with 5 μg/ml TLR7/8 ligands CL097 (InvivoGen, San Diego, CA) for 20 h in the presence of Brefeldin A. After fixation and permeabilization, intracellular cytokine staining was performed using antibodies against IL-6, IL-12p70, TNF-α.
Data were expressed using Box- and Whisker plots, indicating the median, minimum, maximum and the 25th and 75th percentiles. Statistical comparisons were made using Mann Whitney U tests or Wilcoxon rank sum tests, as appropriate.
- Appay V, Sauce D: Immune activation and inflammation in HIV-1 infection: causes and consequences. J Pathol. 2008, 214: 231-241. 10.1002/path.2276.View ArticlePubMedGoogle Scholar
- Schulze Zur Wiesch J, Thomssen A, Hartjen P, Toth I, Lehmann C, Meyer-Olson D, Colberg K, Frerk S, Babikir D, Schmiedel S, et al: Comprehensive analysis of frequency and phenotype of T regulatory cells in HIV infection: CD39 expression of FoxP3+ T regulatory cells correlates with progressive disease. J Virol. 2011, 85: 1287-1297. 10.1128/JVI.01758-10.PubMed CentralView ArticlePubMedGoogle Scholar
- Trautmann L, Janbazian L, Chomont N, Said EA, Gimmig S, Bessette B, Boulassel MR, Delwart E, Sepulveda H, Balderas RS, et al: Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat Med. 2006, 12: 1198-1202. 10.1038/nm1482.View ArticlePubMedGoogle Scholar
- Kaufmann DE, Kavanagh DG, Pereyra F, Zaunders JJ, Mackey EW, Miura T, Palmer S, Brockman M, Rathod A, Piechocka-Trocha A, et al: Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction. Nat Immunol. 2007, 8: 1246-1254. 10.1038/ni1515.View ArticlePubMedGoogle Scholar
- Vlad G, Piazza F, Colovai A, Cortesini R, Della Pietra F, Suciu-Foca N, Manavalan JS: Interleukin-10 induces the upregulation of the inhibitory receptor ILT4 in monocytes from HIV positive individuals. Hum Immunol. 2003, 64: 483-489. 10.1016/S0198-8859(03)00040-5.View ArticlePubMedGoogle Scholar
- Huang J, Burke PS, Cung TD, Pereyra F, Toth I, Walker BD, Borges L, Lichterfeld M, Yu XG: Leukocyte immunoglobulin-like receptors maintain unique antigen-presenting properties of circulating myeloid dendritic cells in HIV-1-infected elite controllers. J Virol. 2010, 84: 9463-9471. 10.1128/JVI.01009-10.PubMed CentralView ArticlePubMedGoogle Scholar
- Allison JP, Pellegrino MA, Ferrone S, Callahan GN, Reisfeld RA: Biologic and chemical characterization of HLA antigens in human serum. J Immunol. 1977, 118: 1004-1009.PubMedGoogle Scholar
- Singh PB, Brown RE, Roser B: Class I transplantation antigens in solution in body fluids and in the urine. Individuality signals to the environment. J Exp Med. 1988, 168: 195-211. 10.1084/jem.168.1.195.View ArticlePubMedGoogle Scholar
- Krangel MS: Secretion of HLA-A and -B antigens via an alternative RNA splicing pathway. J Exp Med. 1986, 163: 1173-1190. 10.1084/jem.163.5.1173.View ArticlePubMedGoogle Scholar
- Dobbe LM, Stam NJ, Neefjes JJ, Giphart MJ: Biochemical complexity of serum HLA class I molecules. Immunogenetics. 1988, 27: 203-210. 10.1007/BF00346587.View ArticlePubMedGoogle Scholar
- Contini P, Ghio M, Merlo A, Brenci S, Filaci G, Indiveri F, Puppo F: Soluble HLA class I/CD8 ligation triggers apoptosis in EBV-specific CD8+ cytotoxic T lymphocytes by Fas/Fas-ligand interaction. Hum Immunol. 2000, 61: 1347-1351. 10.1016/S0198-8859(00)00212-3.View ArticlePubMedGoogle Scholar
- Spaggiari GM, Contini P, Dondero A, Carosio R, Puppo F, Indiveri F, Zocchi MR, Poggi A: Soluble HLA class I induces NK cell apoptosis upon the engagement of killer-activating HLA class I receptors through FasL-Fas interaction. Blood. 2002, 100: 4098-4107. 10.1182/blood-2002-04-1284.View ArticlePubMedGoogle Scholar
- Spaggiari GM, Contini P, Carosio R, Arvigo M, Ghio M, Oddone D, Dondero A, Zocchi MR, Puppo F, Indiveri F, Poggi A: Soluble HLA class I molecules induce natural killer cell apoptosis through the engagement of CD8: evidence for a negative regulation exerted by members of the inhibitory receptor superfamily. Blood. 2002, 99: 1706-1714. 10.1182/blood.V99.5.1706.View ArticlePubMedGoogle Scholar
- Brown D, Trowsdale J, Allen R: The LILR family: modulators of innate and adaptive immune pathways in health and disease. Tissue Antigens. 2004, 64: 215-225. 10.1111/j.0001-2815.2004.00290.x.View ArticlePubMedGoogle Scholar
- Puppo F, Brenci S, Lanza L, Bosco O, Imro MA, Scudeletti M, Indiveri F, Ferrone S: Increased level of serum HLA class I antigens in HIV infection. Correlation with disease progression. Hum Immunol. 1994, 40: 259-266. 10.1016/0198-8859(94)90025-6.View ArticlePubMedGoogle Scholar
- Schwartz O, Marechal V, Le Gall S, Lemonnier F, Heard JM: Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein. Nat Med. 1996, 2: 338-342. 10.1038/nm0396-338.View ArticlePubMedGoogle Scholar
- Lichterfeld M, Kavanagh DG, Williams KL, Moza B, Mui SK, Miura T, Sivamurthy R, Allgaier R, Pereyra F, Trocha A, et al: A viral CTL escape mutation leading to immunoglobulin-like transcript 4-mediated functional inhibition of myelomonocytic cells. J Exp Med. 2007, 204: 2813-2824. 10.1084/jem.20061865.PubMed CentralView ArticlePubMedGoogle Scholar
- Jones DC, Kosmoliaptsis V, Apps R, Lapaque N, Smith I, Kono A, Chang C, Boyle LH, Taylor CJ, Trowsdale J, Allen RL: HLA Class I Allelic Sequence and Conformation Regulate Leukocyte Ig-Like Receptor Binding. J Immunol. 2011Google Scholar
- Donaghy H, Gazzard B, Gotch F, Patterson S: Dysfunction and infection of freshly isolated blood myeloid and plasmacytoid dendritic cells in patients infected with HIV-1. Blood. 2003, 101: 4505-4511. 10.1182/blood-2002-10-3189.View ArticlePubMedGoogle Scholar
- Stacey AR, Norris PJ, Qin L, Haygreen EA, Taylor E, Heitman J, Lebedeva M, DeCamp A, Li D, Grove D, et al: Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections. J Virol. 2009, 83: 3719-3733. 10.1128/JVI.01844-08.PubMed CentralView ArticlePubMedGoogle Scholar
- Valdez H, Lederman MM: Cytokines and cytokine therapies in HIV infection. AIDS Clin Rev. 1997, 187-228.Google Scholar
- Huang J, Burke P, Yang Y, Seiss K, Beamon J, Cung T, Toth I, Pereyra F, Lichterfeld M, Yu XG: Soluble HLA-G inhibits myeloid dendritic cell function in HIV-1 infection by interacting with leukocyte immunoglobulin-like receptor B2. J Virol. 2010, 84: 10784-10791. 10.1128/JVI.01292-10.PubMed CentralView ArticlePubMedGoogle Scholar
- Chang CC, Ciubotariu R, Manavalan JS, Yuan J, Colovai AI, Piazza F, Lederman S, Colonna M, Cortesini R, Dalla-Favera R, Suciu-Foca N: Tolerization of dendritic cells by T(S) cells: the crucial role of inhibitory receptors ILT3 and ILT4. Nat Immunol. 2002, 3: 237-243.View ArticlePubMedGoogle Scholar
- Hunt JS, Petroff MG, McIntire RH, Ober C: HLA-G and immune tolerance in pregnancy. FASEB J. 2005, 19: 681-693. 10.1096/fj.04-2078rev.View ArticlePubMedGoogle Scholar
- Carrington M, O'Brien SJ: The influence of HLA genotype on AIDS. Annu Rev Med. 2003, 54: 535-551. 10.1146/annurev.med.54.101601.152346.View ArticlePubMedGoogle Scholar
- Pereyra F, Jia X, McLaren PJ, Telenti A, de Bakker PI, Walker BD, Ripke S, Brumme CJ, Pulit SL, Carrington M, et al: The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science. 2010, 330: 1551-1557.PubMed CentralView ArticlePubMedGoogle Scholar
- Huang J, Goedert JJ, Sundberg EJ, Cung TD, Burke PS, Martin MP, Preiss L, Lifson J, Lichterfeld M, Carrington M, Yu XG: HLA-B*35-Px-mediated acceleration of HIV-1 infection by increased inhibitory immunoregulatory impulses. J Exp Med. 2009, 206: 2959-66. 10.1084/jem.20091386.PubMed CentralView ArticlePubMedGoogle Scholar
- Tanabe M, Sekimata M, Ferrone S, Takiguchi M: Structural and functional analysis of monomorphic determinants recognized by monoclonal antibodies reacting with the HLA class I alpha 3 domain. J Immunol. 1992, 148: 3202-3209.PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.